Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that improves stability and bioavailability. It is the only GHRH analog with FDA approval — specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution caused by antiretroviral therapy.

What makes Tesamorelin relevant beyond the lipodystrophy population is its demonstrated efficacy for visceral adipose tissue (VAT) reduction — the metabolically dangerous deep abdominal fat that surrounds the organs and drives insulin resistance, cardiovascular risk, hepatic steatosis, and systemic inflammation. VAT is qualitatively different from subcutaneous fat. It is more hormonally active, more resistant to diet and exercise alone, and more closely correlated with cardiometabolic mortality. Tesamorelin reduces VAT through its GHRH-mediated increase in endogenous GH secretion, which stimulates lipolysis preferentially in visceral adipose depots.

This protocol addresses Tesamorelin use for visceral fat reduction in the broader population, including but not limited to HIV-associated lipodystrophy.

Dose selection

Tesamorelin dosing is unusually straightforward compared to other peptide protocols. The FDA-approved dose is the dose used in clinical practice — there is minimal dose-ranging flexibility because the clinical trials that established efficacy used a single fixed dose.

Standard dose: 2 mg (2,000 mcg) subcutaneously, once daily. This is the FDA-approved dose and the dose used in virtually all published clinical trials. It produces consistent increases in endogenous GH secretion and measurable reductions in visceral adipose tissue over 6-12 months.

There is no established low-dose or starter dose for Tesamorelin. Unlike Sermorelin, where dose titration from 100 mcg to 300 mcg is standard practice, Tesamorelin was studied and approved at the 2 mg dose. Some practitioners start at 1 mg for the first week to assess tolerance, but this is a precautionary practice rather than an evidence-based titration strategy. If this approach is used, increase to the full 2 mg dose after 5-7 days.

Dose adjustment considerations: Individuals who experience significant water retention or joint stiffness at 2 mg may benefit from a temporary reduction to 1 mg for 1-2 weeks while the body adapts, followed by a return to 2 mg. However, doses below 2 mg have not been shown to produce clinically meaningful VAT reduction, so remaining at a reduced dose long-term is not recommended.

Why not higher than 2 mg? The dose-response relationship for GHRH analogs is not linear at higher doses. Doubling the dose does not double the GH response — pituitary somatotroph cells have a saturation point for GHRH-stimulated GH release. Doses above 2 mg increase side effects without proportional increases in efficacy.

Route and administration

Route: Subcutaneous injection only. Tesamorelin is a 44-amino-acid peptide with no oral bioavailability.

Injection site: The FDA-approved label specifies abdominal subcutaneous injection. Rotate between quadrants of the abdomen, at least 2 inches from the navel, avoiding areas of active lipodystrophy, bruising, or scarring. The abdomen is preferred because it provides the most consistent absorption for this compound — alternative sites (thigh, upper arm) have not been validated in the pivotal clinical trials.

Timing: Tesamorelin can be administered at any consistent time of day, but there are practical considerations that favor certain timing patterns.

Morning administration (preferred by many practitioners): Tesamorelin on an empty stomach in the morning, before breakfast. This leverages the overnight fasting state (low insulin) to maximize the GH response to GHRH stimulation. Wait 30-60 minutes before eating after injection.

Evening administration (alternative): Thirty minutes before bed, at least 2-3 hours after dinner. This synchronizes the Tesamorelin-stimulated GH release with the natural nocturnal GH pulse during slow-wave sleep. Both timing approaches are valid — the most important factor is consistency, so the body's GH axis can entrain to the daily stimulus.

Key principle — fasting state: Regardless of timing, Tesamorelin must be administered in a fasted or post-absorptive state. Elevated blood glucose and insulin directly suppress GH release by increasing hypothalamic somatostatin tone. Injecting Tesamorelin after a meal substantially reduces the GH response. Minimum 2 hours fasted; 3-4 hours is optimal.

Reconstitution: The commercial product (Egrifta) comes as a lyophilized powder with a diluent (sterile water). For research-grade Tesamorelin, reconstitute with bacteriostatic water. Add slowly along the vial wall, swirl gently — do not shake. Store reconstituted solution at 2-8 degrees Celsius and use within 4 weeks.

Cycle structure

Tesamorelin protocols are longer than most peptide cycles because visceral fat reduction is a slow, cumulative process. The clinical trials that established efficacy ran for 26-52 weeks.

Minimum effective treatment duration: 26 weeks (6 months). The pivotal Phase 3 trials (LIPO-010 and LIPO-011) demonstrated statistically significant VAT reduction at the 26-week mark. Shorter durations may produce some benefit but are unlikely to achieve the magnitude of VAT reduction seen in the clinical data.

Optimal treatment duration: 52 weeks (12 months). Extended studies showed that VAT reduction continues to accrue through 12 months of treatment, with the 52-week data showing greater reductions than the 26-week data. For individuals with substantial visceral adiposity, a full 12-month treatment course is recommended.

Beyond 12 months: The FDA label does not specify a maximum treatment duration. Some practitioners continue Tesamorelin indefinitely in patients with persistent visceral adiposity, with ongoing IGF-1 monitoring. However, VAT reduction appears to plateau after approximately 12 months of treatment, suggesting diminishing returns beyond this point.

Off-treatment considerations — the VAT rebound problem: One of the most important findings from the Tesamorelin literature is that VAT tends to re-accumulate after treatment discontinuation. In the extension studies, patients who stopped Tesamorelin after 26 weeks saw partial re-accumulation of VAT over the subsequent 26 weeks. This is not a "rebound" in the pharmacologic sense — it reflects the return to the underlying metabolic state that caused visceral fat accumulation in the first place. This underscores the importance of addressing the root causes of visceral adiposity (diet, exercise, insulin resistance, sleep, stress) concurrently with Tesamorelin treatment, so that the improvements are sustainable after treatment ends.

Cycling approach (for non-continuous use): If using defined cycles, a minimum of 6 months on treatment followed by 2-3 months off, with body composition reassessment during the off-period to determine whether a repeat cycle is warranted.

Combination options

Tesamorelin's mechanism (GHRH-mediated GH release for preferential visceral fat lipolysis) can be complemented by interventions that address related pathways.

Tesamorelin + Semaglutide: This is a powerful combination for comprehensive metabolic improvement. Semaglutide reduces caloric intake through appetite suppression and improves insulin sensitivity through GLP-1 receptor agonism. Tesamorelin preferentially targets visceral fat through GH-mediated lipolysis. Together, they address total body weight (semaglutide) and visceral fat specifically (tesamorelin). This combination has growing clinical interest in the metabolic medicine community. No pharmacological interaction has been identified, but the GI side effects of semaglutide and the potential water retention from tesamorelin require independent monitoring.

Tesamorelin + AOD-9604: AOD-9604 provides direct lipolytic stimulation of subcutaneous fat through the beta-3 adrenergic pathway, while Tesamorelin targets visceral fat through GH-mediated mechanisms. This combination addresses both fat depots through distinct mechanisms. AOD-9604 (300-500 mcg fasted morning injection) can be timed separately from Tesamorelin (evening injection) for two daily windows of lipolytic activity.

Tesamorelin + Sermorelin: Both are GHRH analogs. Combining them is redundant — both act on the same pituitary receptor. Choose one or the other. Tesamorelin is the superior choice for visceral fat reduction due to its specific clinical evidence for this indication. Sermorelin is the more versatile choice for general anti-aging purposes where VAT is not the primary target.

Tesamorelin + Lifestyle intervention: This is not optional — it is foundational. Tesamorelin addresses the symptom (excess VAT) but not the underlying metabolic drivers. Concurrent interventions should include: caloric deficit or at minimum caloric maintenance at an appropriate level, resistance training (2-4 sessions per week — lean mass supports metabolic rate and insulin sensitivity), cardiovascular exercise (150+ minutes per week of moderate-intensity activity), sleep optimization (7-9 hours, addressing sleep apnea if present — sleep apnea is strongly associated with visceral adiposity), and stress management (chronic cortisol elevation promotes visceral fat deposition).

Monitoring

Tesamorelin monitoring is more structured than most peptide protocols because it has FDA-approved labeling with specific monitoring recommendations.

Baseline testing (before starting):

IGF-1 (fasting, morning draw) — this is the primary safety monitoring parameter
Fasting glucose and HbA1c — Tesamorelin can transiently affect glucose metabolism
Fasting insulin — insulin resistance is both a cause of visceral adiposity and a target of treatment
Lipid panel (total cholesterol, LDL, HDL, triglycerides)
Liver function tests (ALT, AST) — visceral fat is associated with hepatic steatosis; improvement should be tracked
Body composition assessment — DEXA scan is the gold standard for quantifying VAT. If DEXA is unavailable, waist circumference (measured at the iliac crest) is a reasonable proxy, though it does not distinguish visceral from subcutaneous abdominal fat
CT scan of the abdomen (L4-L5 level single slice) provides the most precise VAT quantification but involves radiation and cost that may not be justified for routine monitoring

Follow-up testing (at 12 weeks, 26 weeks, and 52 weeks):

IGF-1 — the FDA label recommends discontinuing Tesamorelin if IGF-1 does not increase. Specifically, if IGF-1 has not risen by at least some measurable amount after 12 weeks, the patient is unlikely to be a GH responder and continued treatment is unlikely to reduce VAT. Conversely, if IGF-1 exceeds the upper limit of the age-adjusted normal range, consider dose reduction
Fasting glucose and HbA1c — GH can impair insulin sensitivity. In clinical trials, mean fasting glucose increased slightly during the first 26 weeks and then stabilized. Clinically significant hyperglycemia requiring intervention occurred in fewer than 5% of treated patients. Monitor and manage accordingly
Body composition (DEXA or waist circumference) at 26 weeks to confirm VAT reduction is occurring
Lipid panel — Tesamorelin has been shown to reduce triglycerides and improve the cholesterol profile in some patients
Liver function tests — hepatic fat fraction may improve with VAT reduction

IGF-1 targets and thresholds:

Target: IGF-1 increase from baseline, remaining within the age-adjusted reference range
Action required: if IGF-1 exceeds the upper limit of normal, reduce dose to 1 mg and recheck in 4-6 weeks
Treatment reconsideration: if IGF-1 does not increase after 12 weeks at 2 mg, the pituitary may have insufficient somatotroph reserve to respond to GHRH stimulation, and Tesamorelin is unlikely to be effective

Side effects and management

Tesamorelin's side effect profile is well-characterized from Phase 3 clinical trials involving over 800 patients.

Injection site reactions: The most common adverse event. Erythema, pruritus, pain, or induration at the injection site reported by approximately 8-13% of patients in clinical trials. Management: rotate injection sites, use proper technique (room-temperature solution, 45-90 degree angle into pinched skin fold, slow injection). Most reactions are mild and do not require discontinuation.

Arthralgia (joint pain): Reported in approximately 11-13% of patients. Related to GH-mediated effects on connective tissue and fluid distribution. Usually mild, affects hands and knees most commonly, and often resolves within the first 4-6 weeks of treatment. Management: maintain adequate hydration, low-dose anti-inflammatory support if needed. If severe or persistent, this may indicate that the GH response is too robust and dose reduction should be considered.

Peripheral edema: Mild water retention, most commonly in the extremities. Reported in approximately 6% of patients. Related to GH-stimulated renal sodium retention. Usually self-limiting within the first month of treatment. Management: moderate sodium intake, adequate hydration, elevate extremities if symptomatic.

Myalgia (muscle pain): Reported in approximately 5-6% of patients. Usually mild and transient. Distinguish from exercise-related soreness, which may change as body composition improves and exercise capacity increases.

Effects on glucose metabolism: Tesamorelin can modestly increase fasting glucose through GH-mediated insulin antagonism. In clinical trials, the mean increase was small (2-5 mg/dL), and clinically significant hyperglycemia was uncommon. However, individuals with pre-existing insulin resistance or prediabetes should monitor glucose closely. If fasting glucose rises above 126 mg/dL or HbA1c exceeds 6.5% during treatment, reassess the risk-benefit ratio with a physician.

Hypersensitivity reactions: Rare. Urticaria, rash, or other allergic-type reactions. Discontinue immediately if these occur and consult a physician.

Carpal tunnel syndrome: Rare but reported with GH-axis therapies. Numbness, tingling, or pain in the hands — particularly at night. Related to fluid accumulation in the carpal tunnel. If symptoms develop, reduce the dose or discontinue until symptoms resolve.

FAQ

How much visceral fat reduction can I expect from Tesamorelin?

In the pivotal clinical trials, Tesamorelin reduced visceral adipose tissue by approximately 15-18% over 26 weeks compared to placebo. Individual responses vary substantially — some patients achieved greater than 25% reduction while others had more modest results. The degree of reduction correlates with the magnitude of the IGF-1 increase, which reflects the individual's pituitary response. If IGF-1 increases robustly, VAT reduction is likely to be meaningful. Extended treatment to 52 weeks produces additional VAT reduction beyond the 26-week results.

Is Tesamorelin only for HIV patients?

Tesamorelin's FDA approval is specifically for HIV-associated lipodystrophy. However, its mechanism — GHRH-stimulated GH release leading to visceral fat lipolysis — is not HIV-specific. The off-label use of Tesamorelin for visceral fat reduction in the general population is growing, driven by the recognition that visceral adiposity is a major cardiometabolic risk factor regardless of its etiology. Practitioners who prescribe Tesamorelin off-label for non-HIV patients use the same dosing and monitoring approach described in this protocol.

Why does visceral fat come back after stopping Tesamorelin?

Tesamorelin treats the excess VAT but does not cure the underlying metabolic drivers that caused it — insulin resistance, sedentary behavior, caloric excess, poor sleep, chronic stress, and aging-related GH decline all continue to promote visceral fat deposition after treatment ends. The re-accumulation observed in clinical trial extension studies reflects this fundamental point. The most effective strategy is to use the Tesamorelin treatment window as an opportunity to establish lifestyle modifications that sustain the improvements independently.

Can Tesamorelin and exogenous GH be used together?

No. This combination is contraindicated. Exogenous GH suppresses endogenous GH production through negative feedback on the pituitary. Tesamorelin works by stimulating the pituitary to produce endogenous GH. Using both simultaneously means the exogenous GH is suppressing the very pathway that Tesamorelin is trying to activate. Choose one approach or the other.

How does Tesamorelin compare to Sermorelin?

Both are GHRH analogs that stimulate endogenous GH release. Tesamorelin is the full 44-amino-acid GHRH sequence with a stabilizing modification; Sermorelin is the truncated first 29 amino acids. Tesamorelin has FDA approval and clinical trial data specifically demonstrating visceral fat reduction. Sermorelin does not have this specific evidence base. Tesamorelin is dosed at 2 mg daily (substantially higher than Sermorelin's 100-300 mcg range), reflecting the different clinical targets: Tesamorelin for aggressive VAT reduction, Sermorelin for more general GH axis optimization. Cost is also a factor — Tesamorelin is typically more expensive than Sermorelin.

Do I need a prescription for Tesamorelin?

Tesamorelin (Egrifta) is a prescription medication in the United States. Legitimate use requires a prescription from a licensed physician. Research-grade Tesamorelin is available from peptide suppliers, but this falls outside the regulatory framework of FDA-approved medication. Regardless of the source, the monitoring protocol described above should be followed to ensure safety.